Publications by authors named "Christian Causse"
Article Synopsis
- Obstructive sleep apnea (OSA) often causes excessive daytime sleepiness (EDS), and pitolisant, a medication that targets histamine receptors, was tested for its efficacy in treating this issue in patients with moderate to severe OSA.
- In a clinical trial with 361 participants, pitolisant was administered in varying doses up to 40 mg daily for 12 weeks, showing a significant reduction in EDS as measured by the Epworth Sleepiness Scale compared to a placebo.
- The study found that pitolisant was well tolerated and improved not only daytime sleepiness but also reaction times and overall patient satisfaction, regardless of whether patients used continuous positive airway pressure (CPAP) therapy.
Background: Obstructive sleep apnoea (OSA) is a common chronic respiratory disease associated with a high burden of disabilities related to sleepiness and reduced quality of life. Despite first-line treatment with continuous positive airway pressure (CPAP) therapy, many patients experience residual excessive daytime sleepiness (EDS). The aim of this study is to compare the relative efficacy and safety of medications authorised for this indication in Europe and/or the United States (modafinil/armodafinil, solriamfetol, and pitolisant) for OSA.
View Article and Find Full Text PDFObjective/background: Chronic obstructive pulmonary disease (COPD), obstructive sleep apnea (OSA) and their comorbid association called Overlap Syndrome (OS) are frequent chronic diseases with high individual and societal burdens. Precise descriptions of the respective symptoms, comorbidities, and medications associated with these three conditions are lacking. We used a multidimensional phenotyping approach to identify relevant phenotypes characterizing these 3 disorders.
View Article and Find Full Text PDFBackground: In people with OSA, excessive daytime sleepiness is a prominent symptom and can persist despite adherence to CPAP, the first-line therapy for OSA. Pitolisant was effective in reducing daytime sleepiness in two 12-week randomized controlled trials (RCTs), one in patients adherent to CPAP (BF2.649 in Patients With OSA and Treated by CPAP But Still Complaining of EDS [HAROSA 1]) and the other in patients refusing or not tolerating CPAP (BF2.
View Article and Find Full Text PDFArticle Synopsis
- Narcolepsy is a chronic condition causing excessive daytime sleepiness and cataplexy, often beginning in childhood, and pitolisant is a medication used to treat it, recently studied for its effects on children aged 6-17.
- This phase 3 study was a double-blind, randomized trial conducted in 11 sleep centers across five countries, focusing on the drug's safety and effectiveness in managing narcolepsy symptoms in young patients.
- Researchers measured the improvement in narcolepsy symptoms using the Ullanlinna Narcolepsy Scale (UNS), comparing the results of those treated with pitolisant to those given a placebo over a structured treatment period.
Article Synopsis
- Excessive daytime sleepiness (EDS) is a common issue for individuals with obstructive sleep apnoea (OSA), linked to complex factors like insufficient sleep and depression, but its clinical measurement is challenging.
- The Epworth Sleepiness Scale is a subjective tool used to assess EDS, though its reliability is under scrutiny, while objective tests like the multiple sleep latency test are not frequently used in OSA patients due to their cost and complexity.
- There are new wake-promoting medications available for EDS in OSA patients in the U.S. and Europe, and this review will explore EDS's significance for OSA diagnosis, its prevalence in treated patients, and the development of treatment options in Europe.
Background: The management of opioid-induced constipation (OIC) is often complicated by the fact that clinical measures of constipation do not always correlate with patient perception. As the discomfort associated with OIC can lead to poor compliance with the opioid treatment, a shift in focus towards patient assessment is often advocated.
Scope: The Bowel Function Index * (BFI) is a new patient-assessment scale that has been developed and validated specifically for OIC.
Constipation assessment scales in adults: a literature review including the new Bowel Function Index.
Expert Rev Gastroenterol Hepatol
October 2011
Constipation is a common clinical condition and patient and physician perception of the disorder can vary considerably. The assessment of a symptom-based condition such as constipation is challenging, in terms of making the diagnosis, assessing the severity of symptoms and their impact on a patient's quality of life, and assessing response to therapy or changes to symptoms over time. In order to assist physicians in assessing the severity of constipation and its related discomfort, several rating scales have been developed.
View Article and Find Full Text PDF